Centre proposes tighter regulatory oversight of antimicrobials to tackle drug resistance

The Health Ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under Central regulatory oversight. The move would require manufacturers to secure prior approval from the Central Licensing Authority...

The Union Health Ministry has proposed bringing antimicrobial medicines under the Central regulatory framework governing new drugs, seeking tighter scrutiny of their quality, safety and efficacy amid growing concerns over antimicrobial resistance (AMR).

The ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, through a draft gazette notification dated November 6. The proposed change seeks to include antimicrobials in the definition of a new drug under Rule 2(1)(w)(v), subjecting them to the regulatory requirements applicable to such medicines.

The move comes against the backdrop of AMR emerging as a major global public health concern, with the ministry calling it a priority that requires coordinated action. The G20 New Delhi Leaders' Declaration had also underscored the need to tackle antimicrobial resistance through a 'One Health' approach.


Explaining the rationale behind the proposed amendment, the ministry flagged concerns over antimicrobial products receiving manufacturing licences without sufficient regulatory scrutiny.

"The proposed amendment has been initiated in view of concerns regarding the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including the requirement for studies such as bioavailability/bioequivalence and stability studies," the ministry said.

It cautioned that the absence of these assessments could compromise the quality and effectiveness of the medicines, with potential consequences for patients and public health.
ADVERTISEMENT

"The absence of such assessments may affect the quality, safety and efficacy of antimicrobial products. Substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety," it added.

Under the proposed framework, manufacturers would have to secure prior permission from the Central Licensing Authority (CLA) before approaching the relevant State Licensing Authority (SLA) for a manufacturing licence.

The requirement is intended to bring antimicrobial products under greater Central oversight and ensure that regulatory assessments are undertaken before manufacturing permissions are granted at the state level.

The ministry said the proposed changes would help strengthen regulatory supervision and ensure that antimicrobial products meet the required standards of quality, safety and efficacy.
ADVERTISEMENT

The draft notification has been opened for objections and suggestions from stakeholders and members of the public. The Centre will consider the feedback before taking up the proposed amendment for finalisation.

Antimicrobials are substances that either kill microorganisms or inhibit their growth. The category includes medicines used to prevent or treat infections, as well as products applied to skin and surfaces to reduce microbial presence.
ADVERTISEMENT

(With inputs from PTI)
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Centre proposes tighter regulatory oversight of antimicrobials to tackle drug resistance
Text Size:AAA
Success
This article has been saved

*

+